Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behcet's disease

Am J Ophthalmol. 2004 Oct;138(4):666-7. doi: 10.1016/j.ajo.2004.04.064.

Abstract

Purpose: To report our experience with intravitreal triamcinolone acetonide (IVTA) injections for the treatment of sight-threatening vitritis.

Design: Interventional case series.

Methods: Three patients with acute severe exacerbations of noninfectious panuveitis and vitritis were treated with IVTA injections alone or as an adjunct to systemic immunosuppressive agents.

Results: Rapid clearance of the vitreous inflammation with improvement in visual acuity was observed 1 to 2 weeks after injection. The effect lasted 2 to 6 months, with the shortest duration in the vitrectomized eye of Patient 1. Repeated injections were required in all patients.

Conclusion: Intravitreal triamcinolone acetonide may be beneficial in selected cases of vitritis. This treatment modality has a rapid effect and may lower the use of systemic agents.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Adolescent
  • Behcet Syndrome / complications
  • Behcet Syndrome / drug therapy*
  • Eye Diseases / drug therapy*
  • Eye Diseases / etiology
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Injections
  • Male
  • Middle Aged
  • Recurrence
  • Triamcinolone Acetonide / therapeutic use*
  • Visual Acuity
  • Vitreous Body / drug effects*
  • Vitreous Body / pathology

Substances

  • Glucocorticoids
  • Triamcinolone Acetonide